X
X. Melody Qu
Researcher at London Health Sciences Centre
Publications - 8
Citations - 953
X. Melody Qu is an academic researcher from London Health Sciences Centre. The author has contributed to research in topics: SABR volatility model & Randomized controlled trial. The author has an hindex of 5, co-authored 6 publications receiving 230 citations. Previous affiliations of X. Melody Qu include University of Western Ontario.
Papers
More filters
Journal ArticleDOI
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Roel Schlijper,Glenn Bauman,Joanna Laba,X. Melody Qu,Andrew Warner,Suresh Senan +23 more
TL;DR: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis and durable over time and there were no new safety signals, and S ABR had no detrimental impact on QOL.
Posted ContentDOI
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Roel Schlijper,Glenn Bauman,Joanna Laba,X. Melody Qu,Andrew Warner,Suresh Senan +23 more
TL;DR: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis, and durable over time, and there were no new safety signals, and S ABR had no detrimental impact on QOL.
Journal ArticleDOI
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET) - Extended Long-Term Outcomes.
Stephen Harrow,David A. Palma,Robert Olson,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Roel Schlijper,Glenn Bauman,Joanna Laba,X. Melody Qu,Andrew Warner,Suresh Senan +21 more
TL;DR: The Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastases (SABR-COMET) randomized phase 2 trial was originally designed with 5 years of follow-up, but the trial was amended in 2016 to extend followup to 10 years as discussed by the authors .
Journal ArticleDOI
A Primer on Interstitial Lung Disease and Thoracic Radiation
Christopher D. Goodman,Suzan F M Nijman,Suresh Senan,Esther J. Nossent,Christopher J. Ryerson,Inderdeep Dhaliwal,X. Melody Qu,Joanna Laba,George Rodrigues,David A. Palma +9 more
TL;DR: This work aims to provide an overview of ILD for the thoracic radiation oncologist, an assessment of risk ofThoracic RT in ILD patients, and evidence based recommendations for treatment for a variety of clinical scenarios.
Journal ArticleDOI
Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial.
X. Melody Qu,Yujie Chen,Gregory S. Zaric,Suresh Senan,Robert Olson,Stephen Harrow,Ava John-Baptiste,Stewart Gaede,Liam Mulroy,Devin Schellenberg,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Andrew Warner,George Rodrigues,David A. Palma,Alexander V. Louie,Alexander V. Louie +18 more
TL;DR: SABR is cost-effective for patients with 1-5 oligometastatic lesions compared to SoC, and this finding was most sensitive to the number of metastatic lesions treated with SABR.